Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Current Leases (2019 - 2025)

Puma Biotechnology's Current Leases history spans 7 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Current Leases fell 76.28% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 76.28%, while the annual FY2025 figure was $1.3 million, 76.28% down from the prior year.
  • Current Leases reached $1.3 million in Q4 2025 per PBYI's latest filing, down from $2.5 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.7 million in Q1 2025 to a low of $1.3 million in Q4 2025.
  • Average Current Leases over 5 years is $4.1 million, with a median of $4.2 million recorded in 2022.
  • Peak YoY movement for Current Leases: grew 17.73% in 2021, then crashed 76.28% in 2025.
  • A 5-year view of Current Leases shows it stood at $3.6 million in 2021, then grew by 15.84% to $4.1 million in 2022, then grew by 15.94% to $4.8 million in 2023, then rose by 15.42% to $5.5 million in 2024, then plummeted by 76.28% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Current Leases are $1.3 million (Q4 2025), $2.5 million (Q3 2025), and $4.4 million (Q2 2025).